Experimental mRNA Cancer Immunotherapy Shows Promise in High-Risk Melanoma, Former FDA Chief Says
核心洞察
An experimental mRNA therapeutic cancer vaccine (搜索) developed by Moderna and Merck (搜索) has shown the ability to help people with high-risk melanoma (搜索) live longer by preventing cancer recurrence.
Former FDA Commissioner Dr. Scott Gottlieb described the approach as a form of cancer immunotherapy, not a traditional vaccine, that trains T cells to recognize cancer-specific proteins.
The therapy delivers mRNA encoding cancer surface proteins to teach the immune system to identify cancer that may have spread beyond surgically removed or chemotherapy-treated tissue.
An experimental mRNA-based therapeutic cancer vaccine developed through a collaboration between Moderna and Merck (搜索) has demonstrated the ability to help people with high-risk melanoma (搜索) live longer, according to former FDA Commissioner Dr. Scott Gottlieb, who discussed the development on "Face the Nation with Margaret Brennan" on Aug. 23, 2026.
Dr. Gottlieb, who serves on the boards of Pfizer and UnitedHealthCare (搜索), characterized the finding as potentially "highly significant," while emphasizing that the treatment is not a vaccine in the traditional sense. "This isn't a vaccine in a traditional sense. This is a form of cancer immunotherapy," he said.
A Decades-Long Pursuit Reaches a Turning Point
Dr. Gottlieb placed the breakthrough in the context of a long scientific effort. "This is something that we've been working on for 30 or 40 years right now, and what's changed is that we have the ability to find proteins on the surface of cancer cells that can be used to try to train the immune system to identify cancer and prevent cancer recurrence," he explained.
The mechanism of action centers on delivering mRNA to train the body to recognize proteins found on the surface of cancer cells. "We are delivering mRNA to try to train the body on proteins that are found on the surface of cancer cells, so that you can teach the T cells in the body to spot the cancer should it recur," Dr. Gottlieb said.
Preventing Recurrence Through Immune Training
The trial's central finding, as described by Dr. Gottlieb, is that the therapy prevents cancer recurrence. "When the body is trained on these specific antigens, the T cells can be able to spot the cancer if it should recur in other parts of the body," he said. This approach targets cancer that may have spread to distant parts of the body and was not removed through surgery or upfront chemotherapy.
Dr. Gottlieb underscored that the treatment belongs to a broader class of immune-training strategies. "There's a lot of different strategies that we use to try to train the immune system to identify cancer and prevent cancer recurrence right now, including CAR-T cells and other kinds of strategies that have been around for decades," he noted. "And that's what this is. It happens to use mRNA to try to elicit those cancer antigens, those cancer proteins that are going to ultimately train T cells to identify cancer."
Awaiting Full Data
Despite the encouraging signals, Dr. Gottlieb urged caution regarding the completeness of the evidence. "We don't have the full results, we have to wait for the top line results to come out," he said, indicating that the findings reported so far represent an interim view of the trial's outcomes.
Dr. Gottlieb also addressed the distinction between this cancer immunotherapy and mRNA vaccines used for infectious diseases, noting that statements from the Department of Health and Human Services regarding reduced federal funding for mRNA vaccine research "pertain, in particular, to mRNA vaccines used for infectious diseases." He reiterated that the melanoma (搜索) treatment is "different" and that "it's a misnomer to call it a vaccine."